Recent Finacing
Recent Raise
Cerecor, a Baltimore clinical-stage biopharma, develops CERC-301—an oral selective NR2B antagonist in Phase 2 for adjunctive treatment of major depressive disorder—and a COMT inhibitor platform for cognitive deficits.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors